Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases
- 1 May 2017
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 141, 19-28
Abstract
No abstract availableKeywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq (APQ 402457/2012-9)
- Fundação Oswaldo Cruz
- Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG (APQ-01797-12, APQ-01070-13)
This publication has 29 references indexed in Scilit:
- Treatment optimization and prediction of HCV clearance in patients with acute HCV infectionJournal of Hepatology, 2013
- Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis CImmunology Letters, 2013
- Targeting the “Cytokine Storm” for Therapeutic BenefitClinical and Vaccine Immunology, 2013
- Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?Retrovirology, 2012
- Cytokine Signatures of Innate and Adaptive Immunity in 17DD Yellow Fever Vaccinated Children and Its Association With the Level of Neutralizing AntibodyThe Journal of Infectious Diseases, 2011
- Association of Serum Cytokine Levels With Treatment Response to Pegylated Interferon and Ribavirin Therapy in Genotype 1 Chronic Hepatitis C PatientsThe Journal of Infectious Diseases, 2011
- IL-8 Is Associated with Non-Viremic State and IFN-γ with Biochemical Activity in HCV-Seropositive Blood DonorsIntervirology, 2010
- Opportunistic autoimmune disordersAnnals of the New York Academy of Sciences, 2010
- Host and viral features in chronic HCV infection: relevance to interferon responsivenessResearch in Virology, 1995
- Interpretation of the Correlation Coefficient: A Basic ReviewJournal of Diagnostic Medical Sonography, 1990